YCBD (cbdmd.com) Future Price to Earnings

Official company branding of cbdMD (YCBD)

The forward P/E ratio for cbdMD, Inc. (YCBD) correlates with the implementation of ESG environmental standards and the transition to biodegradable packaging. The 0.00 mark reflects the asset's current state amid severe pricing pressure within the CBD product niche. Meanwhile, the business relies on full outsourcing of production and logistics, focusing exclusively on marketing and brand visual identity.

cbdMD, Inc. - YCBD Market Cap to Future Earnings Ratio (period 07/04/2022 - 11/12/2026)

Summary analytical data breakdowns for cbdMD Corp (YCBD)

- current price and projected stock value:
Stock Quotes cbdMD, Inc.|YCBD - Fair Value Consensus
- business market valuation indicators:
Market Value cbdMD Inc.|YCBD - Total Enterprise Value
- balance sheet equity data:
Accounting Value per Share cbdMD|YCBD - Total Net Assets|Market Capitalization to Book Value Ratio cbdmd.com|YCBD - Aggregate Asset Value
- debt level and financial liquidity data:
Total Debt to Capital cbdMD, Inc.|YCBD - Long-Term Liabilities to Capital|Short-Term Debt to Equity cbdMD, Inc.|YCBD - Aggregate Debt Obligations|Debts to Book Capitalization cbdMD Inc.|YCBD - Company Long-Term Liabilities|Company Short-Term Debts cbdMD|Quick Ratio cbdmd.com
- financial results and valuation multiples details:
YCBD - Company Profit|Expected Profit cbdMD, Inc.|YCBD - Price to Earnings Ratio|Forward P/E Multiple cbdMD, Inc.|YCBD - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio cbdMD Inc.|YCBD - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) cbdMD|YCBD - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months cbdmd.com|YCBD - Earnings per share growth this year|Earnings growth forecast for next year cbdMD, Inc.
Fundamental valuation:cbdMD
Brand item of cbdMD, Inc.

Over-the-counter cannabidiol product sales for cbdMD, Inc. (YCBD) depend on consumer demand within the self-care segment and are subject to seasonal fluctuations. By analyzing the company's expected P/E valuation, an investor determines the cost of one dollar of projected earnings, which allows for the distinction between a fundamental discount and a systemic business decline given the brand's sensitivity to macroeconomic shocks and household spending.

Competitors of cbdMD, Inc.

Projected Price to Earnings HLN (Haleon)|KVUE (Kenvue Inc) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma Corp VRNA|Jyong Bio (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|amneal.com - Market Cap to Future Earnings Ratio|PRGO: Forward P/E Multiple|Alvotech S.A. - Future Price to Earnings Multiple|LQDA (Liquidia Technologies) - Forward P/E Multiple|Projected Price to Earnings Ratio Galapagos Corp GLPG|Future Price to Earnings ANI Pharmaceuticals (ANIP)|MNKD (mannkindcorp.com) - Future Price to Earnings Multiple|Forward P/E Multiple AMPH (Amphastar Pharmaceuticals, Inc.)|PCRX - Projected Price to Earnings|ARS Pharma - Forward P/E Multiple|TBPH: Future Price to Earnings|AQST: Forward P/E Multiple|Price to Future Earnings Ratio SCPH|Future Price to Earnings Tectonic Therapeutic Inc.|Projected Price to Earnings Tonix Pharma (TNXP)|Forward P/E Multiple SXTC|eupraxiapharma.com - Price to Future Earnings Ratio|BioHarvest Sciences - Projected Price to Earnings|Future Price to Earnings Multiple EXOZ|Oramed Pharma - Forward P/E Multiple|Market Cap to Projected Earnings Entera Bio Ltd. ENTX|MindWalk (HYFT) - Future Price to Earnings|Price to Future Earnings Ratio ABVC|CPIX (Cumberland Pharmaceuticals) - Forward P/E Multiple|Projected Price to Earnings quantumbiopharma.com (QNTM)|Projected Price to Earnings FGEN (FibroGen)|Market Cap to Projected Earnings Telomir Pharmaceuticals Inc|Rani Therapeutics Holdings, Inc. - Projected Price to Earnings|Synergy CHC Corp. (SNYR) - Projected Price to Earnings Ratio|Rallybio Corp. - Forward P/E Multiple|Lexaria Bioscience (LEXX) - Projected Price to Earnings|PULM: Forward P/E Multiple|PTHL (Pheton Holdings) - Future Price to Earnings|APM (Aptorum Group Ltd) - Forward P/E Multiple|Price to Future Earnings Ratio LYRA (Lyra Therapeutics Inc)|Future Price to Earnings Impact BioMedical Inc (IBO)|TNFA: Price to Expected Earnings Ratio|Forward P/E Multiple PRFX (PainReform)|Future Price to Earnings Multiple CYTO|Lipella - Forward P/E Multiple|OPTN - Forward P/E Multiple|Pieris Pharmaceuticals (PIRS) - Future Price to Earnings|procapsgroup.com - Future Price to Earnings Multiple|Future Price to Earnings Petros Pharmaceuticals, Inc.|Projected Price to Earnings Qilian International Holding Group (QLI)|Forward P/E Multiple SLRN|Forward P/E Multiple TFF Pharmaceuticals, Inc (TFFP)